Globus Medical (NYSE:GMED) Stock Rating Cut to Hold at Zacks Research

Globus Medical (NYSE:GMED – Get Free Report) was downgraded by equities researchers at Zacks Research from a “strong-buy” rating to a “hold” rating in a report issued on Monday, Zacks reports.

Several other equities research analysts have also weighed in on GMED. UBS Group began coverage on Globus Medical in a research report on Tuesday, July 28th. They set a “neutral” rating and a $82.00 target price on the stock. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Globus Medical in a report on Friday, October 9th. BTIG Research reiterated a “neutral” rating on shares of Globus Medical in a research note on Friday. Canaccord Genuity Group reduced their price objective on shares of Globus Medical from $115.00 to $105.00 and set a “buy” rating for the company in a research report on Friday, November 6th. Finally, Needham & Company LLC lowered their target price on shares of Globus Medical from $117.00 to $100.00 and set a “buy” rating for the company in a report on Friday, November 6th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and seven have given a Hold rating to the company. Based on data from MarketBeat, Globus Medical currently has a consensus rating of “Moderate Buy” and a consensus target price of $96.08.

View Our Latest Stock Analysis on GMED

Globus Medical Stock Down 1.4%

NYSE GMED opened at $75.31 on Monday. Globus Medical has a 52 week low of $70.39 and a 52 week high of $101.40. The firm has a 50 day moving average of $76.95 and a two-hundred day moving average of $83.00. The stock has a market capitalization of $10.11 billion, a PE ratio of 18.50, a price-to-earnings-growth ratio of 1.18 and a beta of 0.98.

Globus Medical (NYSE:GMED – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The medical device company reported $1.23 earnings per share for the quarter, beating analysts’ consensus estimates of $1.20 by $0.03. The business had revenue of $763.72 million for the quarter, compared to analyst estimates of $792.39 million. Globus Medical had a net margin of 17.76% and a return on equity of 14.43%. The company’s revenue was down .7% on a year-over-year basis. During the same period last year, the business earned $1.18 EPS. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. On average, equities research analysts expect that Globus Medical will post 4.97 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Stephen Zarrilli sold 25,000 shares of the business’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $87.04, for a total value of $2,176,000.00. Following the transaction, the director owned 25,000 shares in the company, valued at $2,176,000. The trade was a 50.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director James R. Tobin sold 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $74.58, for a total value of $2,237,400.00. Following the sale, the director directly owned 15,000 shares of the company’s stock, valued at approximately $1,118,700. This represents a 66.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 60,000 shares of company stock valued at $4,838,400 over the last quarter. 18.38% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Globus Medical

Institutional investors have recently bought and sold shares of the company. Janus Henderson Group PLC increased its stake in shares of Globus Medical by 4.5% during the first quarter. Janus Henderson Group PLC now owns 7,623,095 shares of the medical device company’s stock worth $656,831,000 after acquiring an additional 328,217 shares during the period. Sculptor Capital LP lifted its position in Globus Medical by 1.9% in the first quarter. Sculptor Capital LP now owns 3,058,000 shares of the medical device company’s stock valued at $263,477,000 after purchasing an additional 58,000 shares during the period. Boston Partners boosted its holdings in Globus Medical by 119.7% in the 3rd quarter. Boston Partners now owns 3,415,554 shares of the medical device company’s stock valued at $255,898,000 after purchasing an additional 1,860,564 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in Globus Medical by 2.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,769,897 shares of the medical device company’s stock valued at $152,474,000 after purchasing an additional 33,976 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC increased its position in Globus Medical by 14.3% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,797,215 shares of the medical device company’s stock worth $133,731,000 after purchasing an additional 225,534 shares during the period. 95.16% of the stock is owned by institutional investors and hedge funds.

About Globus Medical

(Get Free Report)

Globus Medical is a medical device company focused on musculoskeletal care. Its products include implants and instruments used in spine surgery, as well as solutions for orthopedic trauma and other orthopedic procedures. The company also develops surgical technologies, including robotic navigation and imaging systems designed to support planning and guidance during procedures. Its portfolio expanded significantly in 2023 when Globus Medical completed its combination with NuVasive, a provider of spine care products and technologies.

Read More

Analyst Recommendations for Globus Medical (NYSE:GMED)

Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.